Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Dartmouth, Alcon, and More

Premium

Title: Determinants of Sensitivity to Chemotherapeutic Agents

Patent Number: 8,673,869

Filed: Dec. 14, 2005

Lead Inventor: Anna De Fazio, University of Sydney


Title: Method of Modulation of Expression of Epidermal Growth Factor Receptor Involving miRNA

Patent Number: 8,673,872

Filed: Aug. 28, 2007

Lead Inventor: Peter Leedman, University of Western Australia


Title: RNAi-mediated Inhibition of Phosphodiesterase Type 4 for Treatment of cAMP-related Ocular Conditions

Patent Number: 8,673,873

Filed: Oct. 16, 2009

Lead Inventor: John Yanni, Alcon


Title: Methods for Treating Pancreatic Cancer

Patent Number: 8,673,874

Filed: Dec. 5, 2011

Inventor: Murray Korc, Dartmouth College


Title: Method for Treating Atherosclerosis

Patent Number: 8,673,875

Filed: Dec. 11, 2012

Lead Inventor: Suh-Hang Juo, Kaohsiung Medical University

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.